Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 25;7:100.
doi: 10.4103/abr.abr_157_17. eCollection 2018.

N-Acetylcysteine as an Adjuvant to Letrozole for Induction of Ovulation in Infertile Patients With Polycystic Ovary Syndrome

Affiliations
Free PMC article

N-Acetylcysteine as an Adjuvant to Letrozole for Induction of Ovulation in Infertile Patients With Polycystic Ovary Syndrome

Fateme Mostajeran et al. Adv Biomed Res. .
Free PMC article

Abstract

Background: This study was aimed to evaluate the influence of oral N-acetylcysteine (NAC) application as an adjuvant to letrozole on induced ovulation outcomes in patients with polycystic ovary syndrome (PCOS).

Materials and methods: This was a placebo-controlled double-blind randomized clinical trial with 130 PCOS patients who were infertile. First, patients were randomly divided into two groups. Patients in Group 1 were administered letrozole 5 mg/d plus NAC 1.2 g/d and patients in Group 2 were administered letrozole plus placebo for 5 days starting at the 3rd day of the menstruation period. On the 12th day of the cycle, ultrasound evaluation was performed, and in whom at least one follicle with an 18-20 mm diameter was found, 10,000 unit human chorionic gonadotropin (hCG) was prescribed, and 36 h after hCG injection, timed intercourse was advised. On the 16th day, after hCG injection, serum β-hCG level was evaluated.

Results: The number of follicles >18 mm was significantly higher in the letrozole + NAC group (P = 0.007). The ovulation and pregnancy rates were also significantly higher in the letrozole + NAC group (P = 0.045). No adverse side effects and no cases of ovarian hyperstimulation syndrome were observed in NAC group.

Conclusion: NAC is demonstrated to be a safe and well-tolerated adjuvant to letrozole and can increase the pregnancy rates in PCOS patients.

Keywords: Letrozole; N-acetylcysteine; ovulation; polycystic ovary syndrome; pregnancy rate.

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Study flowchart
Figure 2
Figure 2
Median and percentile of 25% and 75% of follicle size in two groups

Similar articles

See all similar articles

References

    1. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: Etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7:219–31. - PubMed
    1. Kovacs G, Wood C. The current status of polycystic ovary syndrome. Aust N Z J Obstet Gynaecol. 2001;41:65–8. - PubMed
    1. Guzick D. Polycystic ovary syndrome: Symptomatology, pathophysiology, and epidemiology. Am J Obstet Gynecol. 1998;179:S89–93. - PubMed
    1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) Hum Reprod. 2004;19:41–7. - PubMed
    1. Kitzinger C, Willmott J. 'The thief of womanhood': Women's experience of polycystic ovarian syndrome. Soc Sci Med. 2002;54:349–61. - PubMed
Feedback